Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors

Stephana Carelli, Toniella Giallongo, Cristina Viaggi, Elisa Latorre, Zuzana Gombalova, Andrea Raspa, Massimiliano Mazza, Francesca Vaglini, Anna Maria Di Giulio, Alfredo Gorio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

An extensive literature has shown a powerful neuroprotective action of Erythropoietin (EPO) both in vivo and in vitro. This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice. Unilateral stereotaxic injection of 2.5 × 105 erythropoietin-releasing neural precursor cells (Er-NPCs) rescued degenerating striatal dopaminergic neurons and promoted behavioral recovery as shown by three independent behavioral tests. These effects were replicated through direct intrastriatal administration of recombinant human EPO. At the end of the observational period, most of the transplanted Er-NPCs were vital and migrated via the striatum to reach Substantia Nigra. The restorative effects appear to be mediated by EPO since co-injection of anti-EPO or anti-EPOR antibodies antagonized the positive outcomes. Furthermore, this report supports the neuroprotective action of EPO, which may also be achieved via administration of EPO-releasing cells such as Er-NPCs.

Original languageEnglish
Pages (from-to)76-90
Number of pages15
JournalNeuropharmacology
Volume119
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Parkinsonian Disorders
Erythropoietin
MPTP Poisoning
Corpus Striatum
Injections
Dopaminergic Neurons
Substantia Nigra
Anti-Idiotypic Antibodies

Keywords

  • Adult stem cells
  • Cell therapy
  • Erythropoietin
  • MPTP
  • Parkinson's disease
  • Regenerative medicine

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors. / Carelli, Stephana; Giallongo, Toniella; Viaggi, Cristina; Latorre, Elisa; Gombalova, Zuzana; Raspa, Andrea; Mazza, Massimiliano; Vaglini, Francesca; Di Giulio, Anna Maria; Gorio, Alfredo.

In: Neuropharmacology, Vol. 119, 01.06.2017, p. 76-90.

Research output: Contribution to journalArticle

Carelli, S, Giallongo, T, Viaggi, C, Latorre, E, Gombalova, Z, Raspa, A, Mazza, M, Vaglini, F, Di Giulio, AM & Gorio, A 2017, 'Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors', Neuropharmacology, vol. 119, pp. 76-90. https://doi.org/10.1016/j.neuropharm.2017.03.035
Carelli, Stephana ; Giallongo, Toniella ; Viaggi, Cristina ; Latorre, Elisa ; Gombalova, Zuzana ; Raspa, Andrea ; Mazza, Massimiliano ; Vaglini, Francesca ; Di Giulio, Anna Maria ; Gorio, Alfredo. / Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors. In: Neuropharmacology. 2017 ; Vol. 119. pp. 76-90.
@article{8455c38aeb6646a1b80611282cb4fe7f,
title = "Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors",
abstract = "An extensive literature has shown a powerful neuroprotective action of Erythropoietin (EPO) both in vivo and in vitro. This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice. Unilateral stereotaxic injection of 2.5 × 105 erythropoietin-releasing neural precursor cells (Er-NPCs) rescued degenerating striatal dopaminergic neurons and promoted behavioral recovery as shown by three independent behavioral tests. These effects were replicated through direct intrastriatal administration of recombinant human EPO. At the end of the observational period, most of the transplanted Er-NPCs were vital and migrated via the striatum to reach Substantia Nigra. The restorative effects appear to be mediated by EPO since co-injection of anti-EPO or anti-EPOR antibodies antagonized the positive outcomes. Furthermore, this report supports the neuroprotective action of EPO, which may also be achieved via administration of EPO-releasing cells such as Er-NPCs.",
keywords = "Adult stem cells, Cell therapy, Erythropoietin, MPTP, Parkinson's disease, Regenerative medicine",
author = "Stephana Carelli and Toniella Giallongo and Cristina Viaggi and Elisa Latorre and Zuzana Gombalova and Andrea Raspa and Massimiliano Mazza and Francesca Vaglini and {Di Giulio}, {Anna Maria} and Alfredo Gorio",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.neuropharm.2017.03.035",
language = "English",
volume = "119",
pages = "76--90",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors

AU - Carelli, Stephana

AU - Giallongo, Toniella

AU - Viaggi, Cristina

AU - Latorre, Elisa

AU - Gombalova, Zuzana

AU - Raspa, Andrea

AU - Mazza, Massimiliano

AU - Vaglini, Francesca

AU - Di Giulio, Anna Maria

AU - Gorio, Alfredo

PY - 2017/6/1

Y1 - 2017/6/1

N2 - An extensive literature has shown a powerful neuroprotective action of Erythropoietin (EPO) both in vivo and in vitro. This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice. Unilateral stereotaxic injection of 2.5 × 105 erythropoietin-releasing neural precursor cells (Er-NPCs) rescued degenerating striatal dopaminergic neurons and promoted behavioral recovery as shown by three independent behavioral tests. These effects were replicated through direct intrastriatal administration of recombinant human EPO. At the end of the observational period, most of the transplanted Er-NPCs were vital and migrated via the striatum to reach Substantia Nigra. The restorative effects appear to be mediated by EPO since co-injection of anti-EPO or anti-EPOR antibodies antagonized the positive outcomes. Furthermore, this report supports the neuroprotective action of EPO, which may also be achieved via administration of EPO-releasing cells such as Er-NPCs.

AB - An extensive literature has shown a powerful neuroprotective action of Erythropoietin (EPO) both in vivo and in vitro. This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice. Unilateral stereotaxic injection of 2.5 × 105 erythropoietin-releasing neural precursor cells (Er-NPCs) rescued degenerating striatal dopaminergic neurons and promoted behavioral recovery as shown by three independent behavioral tests. These effects were replicated through direct intrastriatal administration of recombinant human EPO. At the end of the observational period, most of the transplanted Er-NPCs were vital and migrated via the striatum to reach Substantia Nigra. The restorative effects appear to be mediated by EPO since co-injection of anti-EPO or anti-EPOR antibodies antagonized the positive outcomes. Furthermore, this report supports the neuroprotective action of EPO, which may also be achieved via administration of EPO-releasing cells such as Er-NPCs.

KW - Adult stem cells

KW - Cell therapy

KW - Erythropoietin

KW - MPTP

KW - Parkinson's disease

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=85017263577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017263577&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2017.03.035

DO - 10.1016/j.neuropharm.2017.03.035

M3 - Article

C2 - 28373075

AN - SCOPUS:85017263577

VL - 119

SP - 76

EP - 90

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -